Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Revenue (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Revenue for 5 consecutive years, with $25000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Revenue fell 87.18% to $25000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$934000.0, a 163.49% decrease, with the full-year FY2023 number at $1.6 million, up 14.31% from a year prior.
  • Revenue was $25000.0 for Q3 2025 at Lyra Therapeutics, down from $183000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $598000.0 in Q2 2024 to a low of -$1.3 million in Q4 2024.
  • A 5-year average of $211588.2 and a median of $271000.0 in 2021 define the central range for Revenue.
  • Peak YoY movement for Revenue: surged 2464.29% in 2022, then crashed 1007.53% in 2024.
  • Lyra Therapeutics' Revenue stood at $271000.0 in 2021, then tumbled by 95.94% to $11000.0 in 2022, then surged by 1227.27% to $146000.0 in 2023, then plummeted by 1007.53% to -$1.3 million in 2024, then soared by 101.89% to $25000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Revenue are $25000.0 (Q3 2025), $183000.0 (Q2 2025), and $183000.0 (Q1 2025).